Clinical Trials

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).

The primary objective of the study is to demonstrate the safety and efficacy of SPG stimulation with the ATI Neurostimulation System when used to treat acute cluster attacks in chronic cluster headache patients.

The purpose of this study is to investigate the use of rimegepant for the treatment of cluster headache. 

The primary purpose of this study is to demonstrate the safety and effectiveness of sphenopalatine ganglion stimulation with the Autonomic Technologies, Inc. Neurostimulation System when used to treat acute cluster attacks in chronic cluster headache patients.

The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as LY2951742 for the treatment of patients who have episodic cluster headaches.

The purpose of this study is to evaluate treatment effects, including safety, and is intended to show a statistically significant effect on number of attacks during the cluster headache bout.

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic cluster headache.

The main purpose of this extended study is to evaluate the long term effectiveness of the study drug LY2951742 in patients who have chronic cluster headaches.

The purpose of this study is to enroll in a registry patients who have headache disorders, collecting detailed headache characteristics, biospecimens, and brain imaging data, to allow for more research into accurate diagnosis, prognosis, and treatments.